Compounds > urea

urea and olaparib

urea has been researched along with olaparib in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Brown, JL; Lawrence, TS; Liu, E; Maybaum, J; Morgan, MA; Parsels, JD; Parsels, LA; Vance, S; Zhao, L1
Aparicio, AM; Broom, B; Chang, W; Corn, PG; Dobashi, M; Efstathiou, E; Karanika, S; Karantanos, T; Lee, HS; Lee, JS; Li Ning Tapia, EM; Li, L; Maity, SN; Navone, N; Park, S; Ren, C; Shah, PK; Takahiro, H; Thompson, TC; Troncoso, P; Wang, J; Xiao, L; Yang, G; Yin, J; Zhang, W1
Babich, JW; Mairs, RJ; Nixon, C; Rae, C; Tesson, M1

Other Studies

3 other study(ies) available for urea and olaparib

ArticleYear
Selective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1.
    Cell cycle (Georgetown, Tex.), 2011, Dec-15, Volume: 10, Issue:24

    Topics: Analysis of Variance; Cell Cycle Checkpoints; Checkpoint Kinase 1; DNA Repair; Drug Combinations; Flow Cytometry; Histones; Humans; Immunoblotting; Intestinal Mucosa; Mutation; Pancreatic Neoplasms; Phthalazines; Piperazines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Protein Kinases; Radiation Tolerance; Radiation-Sensitizing Agents; Thiophenes; Tumor Suppressor Protein p53; Urea

2011
Targeting poly(ADP-ribose) polymerase and the c-Myb-regulated DNA damage response pathway in castration-resistant prostate cancer.
    Science signaling, 2014, May-20, Volume: 7, Issue:326

    Topics: Animals; BRCA1 Protein; Carrier Proteins; Castration; Cell Cycle Checkpoints; DNA Damage; DNA-Binding Proteins; Humans; Male; Mice; Mice, Nude; Nuclear Proteins; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Prostatic Neoplasms; Proto-Oncogene Proteins c-myb; Receptors, Androgen; Thiophenes; Urea; Xenograft Model Antitumor Assays

2014
Preliminary evaluation of prostate-targeted radiotherapy using (131) I-MIP-1095 in combination with radiosensitising chemotherapeutic drugs.
    The Journal of pharmacy and pharmacology, 2016, Volume: 68, Issue:7

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cell Line, Tumor; Cell Proliferation; Disulfiram; Glutamates; Humans; Imidazoles; Iodine Radioisotopes; Male; Molecular Targeted Therapy; Phthalazines; Piperazines; Prostate; Spheroids, Cellular; Thiophenes; Topotecan; Tumor Cells, Cultured; Urea

2016